How to buy Travere Therapeutics stock (TVTX)

Travere Therapeutics is a biotechnology business based in the US. Travere Therapeutics shares (TVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.13 – an increase of 1.6% over the previous week. Travere Therapeutics employs 380 staff and has a trailing 12-month revenue of around $203.4 million.

Our top picks for where to buy Travere Therapeutics stock

Buy Travere Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Travere Therapeutics stock price (NASDAQ: TVTX)

Use our graph to track the performance of TVTX stocks over time.

Travere Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$17.13
52-week range	$5.12 - $20.33
50-day moving average more info button	$18.09
200-day moving average more info button	$11.05
Wall St. target price	$27.40
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.52

Is it a good time to buy Travere Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Travere Therapeutics price performance over time

Historical closes compared with the close of $17.15 from 2024-12-23

1 week (2024-12-18)	1.72%
1 month (2024-11-25)	-5.67%
3 months (2024-09-25)	17.95%
6 months (2024-06-25)	115.45%

1 year (2023-12-22)	89.29%
2 years (2022-12-23)	-14.38%
3 years (2021-12-23)	31.17
5 years (2019-12-24)	13.58%

Travere Therapeutics financials

Revenue TTM	$203.4 million
Gross profit TTM	$-31,354,000
Return on assets TTM	-26.14%
Return on equity TTM	-279.94%
Profit margin	-172.75%
Book value	$-0.39
Market Capitalization more info button	$1.5 billion

TTM: trailing 12 months

Travere Therapeutics share dividends

We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.

Have Travere Therapeutics's shares ever split?

Travere Therapeutics's shares were split on a 1:9 basis on 7 November 2011 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.

Travere Therapeutics share price volatility

Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $5.12 up to $20.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.7. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).

Travere Therapeutics overview

Travere Therapeutics, Inc. , a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U. S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.

Frequently asked questions

What percentage of Travere Therapeutics is owned by insiders or institutions?
Currently 0.652% of Travere Therapeutics shares are held by insiders and 98.991% by institutions. How many people work for Travere Therapeutics?
Latest data suggests 380 work at Travere Therapeutics. When does the fiscal year end for Travere Therapeutics?
Travere Therapeutics's fiscal year ends in December. Where is Travere Therapeutics based?
Travere Therapeutics's address is: 3611 Valley Centre Drive, San Diego, CA, United States, 92130 What is Travere Therapeutics's ISIN number?
Travere Therapeutics's international securities identification number is: US89422G1076